EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treosulfan vs leuprorelin in platin- and paclitaxel-resistant ovarian cancer Final analysis of the German AGO-Study Group trial OVAR 21



Treosulfan vs leuprorelin in platin- and paclitaxel-resistant ovarian cancer Final analysis of the German AGO-Study Group trial OVAR 21



European Journal of Cancer 37(Supplement 6): S325, October




(PDF same-day service: $19.90)

Accession: 035985738

Download citation: RISBibTeXText

DOI: 10.1016/S0959-8049(01)81694-4



Related references

Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecologic Oncology 114(2): 199-205, 2009

Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecologic Oncology 105(1): 132-137, 2006

Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy- A phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecologic Oncology 105(1): 132-137, 2007

Topotecan versus treosulfan in recurrent ovarian cancer after initial chemotherapy with platinum and paclitaxel A prospective randomised phase III study of the AGO Ovarian Cancer Study Group. EJC Supplements 1(5): S16, September, 2003

Treatment of patients with advanced ovarian cancer with cisplatin/paclitaxel or carboplatin/paclitaxel - An interim analysis of the ago study protocol ovar-3. European Journal of Cancer 35(SUPPL 4): S231, Sept, 1999

Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. Seminars in Oncology 24(5 Suppl 15): S15-44-S15-52, 1997

Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Annals of Oncology 13(2): 251-257, 2002

Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. International Journal of Gynecological Cancer 19(1): 109-115, 2009

A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8). Gynecologic Oncology 96(2): 444-451, 2005

Pre-operative selection criteria for operability in recurrent ovarian cancer. A study of the AGO Organkommission Ovar and the AGO Ovarian Cancer Study Group (AGO-OVAR). Journal of Clinical Oncology 23(16_suppl): 5004-5004, 2016

Oral treosulfan as second-line treatment in platinum-resistant ovarian cancer: a phase II study. The Danish Ovarian Cancer Study Group. Gynecologic Oncology 69(2): 100-102, 1998

Efficacy and safety of leuprorelin acetate depot for prostate cancer. The German Leuprorelin Study Group. Urologia Internationalis 56 Suppl 1: 23-30, 1996

Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute 98(15): 1036-1045, 2006

Paclitaxel/carboplatin (TC) vs. paclitaxel/carboplatin followed by topotecan (TOP) in first-line treatment of advanced ovarian cancer. Mature results of a Gynecologic Cancer Intergroup phase III trial of the AGO OVAR and GINECO. Journal of Clinical Oncology 23(16_suppl): Lba5007-Lba5007, 2016